Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Aldeyra gets a win in its second pivotal dry eye trial of reproxalap, but only after some serious tinkering.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.